Ruxolitinib Cream for Pediatric Atopic Dermatitis: What Clinicians Need to KnowÂ
The U.S. Food and Drug Administration (FDA) recently expanded the indication for ruxolitinib cream (Opzelura®) to include children aged 2–11 years with mild-to-moderate atopic dermatitis (AD). This topical, non-steroidal therapy, previously approved for patients 12 years and older, offers a new, targeted approach to managing pediatric AD while reducing concerns associated with chronic corticosteroid use. […]
FDA Approves ZORYVE® Foam 0.3%: A New Topical Option for Scalp and Body Psoriasis
In a significant development for psoriasis treatment, the U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) topical foam 0.3%, for the treatment of plaque psoriasis, including intertriginous areas, in adults and pediatric patients aged 12 years and older. This approval offers a new, steroid-free, once-daily topical therapy for patients with psoriasis affecting the […]
FDA Recently Approves Combination Treatment for Melanoma
The rates of melanoma have been consistently rising in the last three decades: statistics from the American Cancer Society indicate that about 91,270 new melanomas will be diagnosed in 2018; approximately 9,320 people will die of melanoma in the same year. In light of the rapid rise of both melanoma and overall skin cancer cases, […]
